Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide injections, including the 1ml dose of Wegovy, most commonly cause gastrointestinal symptoms such as nausea, loose stools or stomach discomfort. These effects typically appear in the days after a dose and settle for most people within one to two weeks. Wegovy is a prescription-only medicine — a prescriber assesses whether it is clinically appropriate for you before treatment begins, and that same clinical eye stays with you throughout. Understanding which side effects are expected, which ones call for a phone call to your GP, and which are genuine emergencies is the decision this page helps you make.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The 1ml Wegovy pen delivers semaglutide as part of the licensed once-weekly titration schedule. When patients move through the dose steps, the gastrointestinal system tends to be the first to respond. Nausea is the most common experience, followed by loose stools, constipation, indigestion, burping and occasionally vomiting. Fatigue and mild headaches are also reported, though less consistently.
Most of this stems from the way semaglutide slows gastric emptying. Food moves through the stomach more slowly, which dampens appetite but can leave some people feeling unsettled, particularly around mealtimes. The NHS patient information for semaglutide notes that these effects are generally most pronounced after a dose increase and tend to ease as your body adjusts.
Practically, the timing matters. Taking your injection on a day when you do not have demanding plans the following morning can make the early weeks easier — some people time it so any grogginess has passed well before the busier part of their week begins. Injection-site reactions, typically mild redness or tenderness, are worth noting in the skin you rotate to; they rarely persist beyond a day or two. If you want a detailed breakdown of what side effects from Wegovy people commonly report, including how they vary by dose step, that is worth reading alongside the broader picture of how Wegovy side effects tend to present across the full treatment course.
The decision most people face is not dramatic. It is quieter: should I wait this out, or should I call someone? The honest answer depends on the character of the symptom, not just its presence.
Nausea that follows a dose and fades within a few days is expected. So is a looser bowel on a titration week. What is not expected is symptom that keeps intensifying, prevents you from keeping fluids down for more than a day, or feels qualitatively different from the GI discomfort described above. Severe dehydration from repeated vomiting can affect kidney function, so losing fluids consistently is a reason to seek advice rather than push through.
Some people find that certain foods make nausea worse on treatment days: large, fatty or heavily spiced meals tend to be the main culprits. Smaller, plainer meals and adequate hydration (water, not just tea or coffee) help. If side effects feel persistent rather than transitional, understanding how long Wegovy side effects typically last may help frame expectations before you decide whether to contact a clinician. And if you are finding symptoms more manageable than expected, that is entirely normal too, some patients experience very little disruption on Wegovy, which is not a sign something is wrong.
A small number of side effects require prompt medical attention. The MHRA issued a Drug Safety Update in January 2026 specifically on GLP-1 medicines and acute pancreatitis: a known but infrequent risk that can be serious. The symptom to act on is severe, persistent pain in the upper abdomen that radiates towards the back, with or without vomiting. This is not the same as ordinary nausea. Stop and contact a healthcare professional or go to A&E if the pain is intense and does not pass quickly.
Gallbladder symptoms are another consideration. Pain in the upper right abdomen, particularly after eating, can signal gallstones, which occur at a higher rate in people losing weight rapidly. Allergic reactions (swelling of the face or throat, difficulty breathing, a sudden rash) need emergency attention. Changes in vision in people who also have diabetes should be discussed with a doctor promptly. Low mood or thoughts of self-harm, though rare, are listed in the prescribing information and should never be dismissed.
If you are not sure whether a symptom is serious, that uncertainty itself is a reason to reach out. Your GP is the right first call for anything that concerns you. Suspected side effects (whether expected or unexpected) can also be logged with the MHRA's Yellow Card scheme, which exists precisely to build a fuller picture of medicines in real-world use. If you are a patient with questions specific to your treatment, our aftercare team is available seven days a week.
Side effects do not exist in isolation from the clinical relationship. The five most commonly reported Wegovy side effects are well-characterised and usually manageable, but how they affect you depends on your individual health picture: other medicines you take, your baseline GI health, your pace of titration. That is why a prescriber rather than a generic protocol makes the call on whether to slow a titration, hold a dose, or (rarely) consider whether treatment should continue.
At nume, every repeat order is reviewed by a GPhC-registered Independent Prescriber before anything is dispensed. There is no algorithm deciding you are fine to continue; a real clinician reads your update. If side effects came up during a previous supply period, that information feeds directly into the next review. For anyone weighing whether to start, the consultation covers suitability and side effects as part of the same conversation, not as an afterthought. You can explore how treatment works and what the process looks like on our treatment page, or take a broader look at what Wegovy involves from the beginning.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.